Neuroimaging Christopher Bever, MD, MBA (MODERATOR) Use of ...
Neuroimaging Christopher Bever, MD, MBA (MODERATOR) Use of ... Neuroimaging Christopher Bever, MD, MBA (MODERATOR) Use of ...
from pva.org
More from this publisher
04.06.2014
Views
Use of MRI to Determine Treatment Response Responders - Non-Responders Complications of Therapy
More specifically --- Can we monitor treatment response to disease modifying therapy by MRI in individual patients ? In Principle Any Disease Modifying Therapy
- Page 1 and 2: Neuroimaging Christopher Bever, MD,
- Page 3 and 4: Disclaimer • The speaker has rece
- Page 5 and 6: MRI in the Individual Patient (As O
- Page 7 and 8: FROM SIMPLE TO COMPLEX T2-Lesions G
- Page 9 and 10: Gadolinium Enhancing Lesions Cell T
- Page 11 and 12: T2 Lesions Non-Specific Pathology I
- Page 13 and 14: Distribution--Periventricular >> Pe
- Page 15 and 16: T1 “Black Holes” A subset of T2
- Page 17 and 18: Spinal Cord Proton/T2 Proton densit
- Page 19 and 20: Number Lesions Most of the Disease
- Page 21 and 22: MRI in Diagnostic Criteria
- Page 23 and 24: Accurate Prediction of Earliest MS
- Page 25 and 26: Barkoff Combined Criteria More Accu
- Page 27 and 28: McDonald Criteria Annals of Neurolo
- Page 29 and 30: Earlier Diagnosis of MS with MRI Ev
- Page 31 and 32: The Criteria are Imperfect - Vigila
- Page 33: Both criteria highly specific (>90%
- Page 36 and 37: 2003 Cortical Lesions only in retro
- Page 38 and 39: Okuda et al. Neurology 2009;72:800
- Page 40 and 41: Use of MRI to Follow Subclinical Di
- Page 42 and 43: 1 4 7 10 13 16 19 22 25 28 37 40 43
- Page 46 and 47: Evaluating the Therapeutic Response
- Page 48 and 49: Two year follow-up ; Outcome = Disa
- Page 50 and 51: Treated Patients with 2 or more les
- Page 52 and 53: New atypical weakness or seizure In
- Page 54 and 55: PML Concern is Detecting PML +MS
- Page 56 and 57: Yousry et al. NEJM;2006 354:924-933
- Page 59 and 60: Standardized MRI For Improved Care
- Page 61 and 62: Standardized MRI Guidelines PD opti
- Page 63 and 64: Update T. Traboulsee et al In 2009
- Page 65 and 66: Field Strength Matters Sicotte, 200
- Page 67 and 68: We Expect 3D Acquisitions to become
- Page 69 and 70: 3D FLAIR - 1mm partitions reconstru
- Page 71 and 72: MRI Signal and Field Strength 3T sc
- Page 73 and 74: 7T MS MPRAGE 0.8 mm thick AIRC at O
- Page 75 and 76: MS, Fe Permeability Study OHSU 7T,
- Page 77 and 78: Summary- And Learning • Classical
<strong>Use</strong> <strong>of</strong> MRI to Determine<br />
Treatment Response<br />
Responders - Non-Responders<br />
Complications <strong>of</strong> Therapy
Change language